Format

Send to

Choose Destination
Nat Commun. 2018 Aug 24;9(1):3430. doi: 10.1038/s41467-018-05764-7.

Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy.

Author information

1
Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
2
School of Materials Science and Engineering of Sun Yat-Sen University, Guangzhou, 510275, China.
3
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
4
Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China.
5
Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. kuangm@mail.sysu.edu.cn.
6
Cancer Center & Precision Medicine Institute, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. shuaixt@mail.sysu.edu.cn.
7
School of Materials Science and Engineering of Sun Yat-Sen University, Guangzhou, 510275, China. shuaixt@mail.sysu.edu.cn.

Abstract

There exists an urgent medical demand at present to develop therapeutic strategies which can improve the treatment outcome of hepatocellular carcinoma (HCC). Here, we explore the biological functions and clinical significance of PBOV1 in HCC in order to push forward the diagnosis and treatment of HCC. Using theranostical nanomedicines, PBOV1 is verified to be a key oncogene which greatly promotes HCC proliferation, epithelial-to-mesenchymal transition, and stemness by activating the Wnt/β-catenin signaling pathway. Therefore, single-chain antibody for epidermal growth factor receptor (scAb-EGFR)-targeted nanomedicine effectively silencing the PBOV1 gene exhibits potent anticancer effects. In vivo HCC-targeting siRNA delivery mediated by the theranostical nanomedicine remarkably inhibits the tumor growth and metastasis. In addition, the superparamagnetic iron oxide nanocrystals (SPION)-encapsulated nanomedicines possess high MRI detection sensitivity, which endows them with the potential for MRI diagnosis of HCC. This study shows that PBOV1 represents a prognostic biomarker and therapeutic target for HCC.

PMID:
30143633
PMCID:
PMC6109108
DOI:
10.1038/s41467-018-05764-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center